Get started
Author

Desi Pan

Observed names: D. S. Pan, De-Si Pan, De‐Si Pan
ORCID: 0000-0002-2104-3902
Observed ORCID: 0000-0002-2104-3902
OpenAlex ID: A5079606398
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
2011 · Zhi-Qiang Ning, Zhi-Bin Li, et al. · Cancer Chemotherapy and Pharmacology · 305
Advances in targeting histone deacetylase for treatment of solid tumors
2024 · Mu-Qi Shi, Ying Xu, et al. · Journal of Hematology & Oncology · 181
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment
2022 · Yichen Sun, Jing Han Hong, et al. · Frontiers in Pharmacology · 94
PDF
High RhoA activity maintains the undifferentiated mesenchymal cell phenotype, whereas RhoA down-regulation by laminin-2 induces smooth muscle myogenesis
2002 · Safedin Beqaj, Sandhya Jakkaraju, et al. · The Journal of Cell Biology · 84
P311 induces a TGF-β1–independent, nonfibrogenic myofibroblast phenotype
2002 · Desi Pan, Xiaoning Zhe, et al. · Journal of Clinical Investigation · 80
Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells
2014 · You Zhou, De-Si Pan, et al. · Biomedicine & Pharmacotherapy · 75
TIPs Are Tension-Responsive Proteins Involved in Myogenic versus Adipogenic Differentiation
2005 · Sandhya Jakkaraju, Xiaoning Zhe, et al. · Developmental Cell · 73
PDF
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
2021 · Linong Ji, Weihong Song, et al. · 中国科学通报：英文版 · 68
PDF
Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment
2014 · De-Si Pan, Qian-Jiao Yang, et al. · MedChemComm · 62
In VitroandIn VivoCharacterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist
2012 · B. K. He, Z. Q. Ning, et al. · PPAR Research · 56
PDF
Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)
2021 · Weiping Jia, Jianhua Ma, et al. · 中国科学通报：英文版 · 50
PDF
CS 2164, a novel multi‐target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti‐tumor potency
2016 · You Zhou, Song Shan, et al. · Cancer Science · 49
PDF
Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ
2017 · De-Si Pan, Wei Wang, et al. · PPAR Research · 44
PDF
Pharmacokinetic Optimization of Class-Selective Histone Deacetylase Inhibitors and Identification of Associated Candidate Predictive Biomarkers of Hepatocellular Carcinoma Tumor Response
2012 · Jason C. Wong, Guozhi Tang, et al. · Journal of Medicinal Chemistry · 29
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARα selective activators
2004 · Zhibin Li, Chenzhong Liao, et al. · Bioorganic & Medicinal Chemistry Letters · 20
Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis
2019 · Song Shan, You Zhou, et al. · International Immunopharmacology · 18
Plasma proteome profiling reveals the therapeutic effects of the PPAR pan-agonist chiglitazar on insulin sensitivity, lipid metabolism, and inflammation in type 2 diabetes
2024 · Xingyue Wang, You Wang, et al. · Scientific Reports · 17
PDF
Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models
2019 · You Zhou, Chao Fu, et al. · Anti-Cancer Drugs · 14
Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas
2021 · Xu Huang, Nan Bi, et al. · Journal of Oncology · 13
PDF
Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy
2010 · Jason C. Wong, Lei Guo, et al. · Bioorganic & Medicinal Chemistry Letters · 12
CS27109, A Selective Thyroid Hormone Receptor-β Agonist Alleviates Metabolic-Associated Fatty Liver Disease in Murine Models
2023 · Shengjian Huang, Zhou Deng, et al. · International Journal of Endocrinology · 11
PDF
Impact of chiglitazar on glycemic control in type 2 diabetic patients with metabolic syndrome and insulin resistance: A pooled data analysis from two phase III trials
2023 · Zhiqiang Ning, Guoqiang Ai, et al. · Journal of Diabetes · 10
Discovery and Development of HDAC Subtype Selective Inhibitor Chidamide: Potential Immunomodulatory Activity Against Cancers
2016 · Xian‐Ping Lu, Zhi‐Qiang Ning, et al. · Wiley eBooks · 9
P311 induces a TGF-β1–independent, nonfibrogenic myofibroblast phenotype
2002 · Desi Pan, Xiaoning Zhe, et al. · Journal of Clinical Investigation · 3
PDF
CS12192, a novel JAK3/JAK1/TBK1 inhibitor, attenuates autoimmune dermatoses in murine models
2024 · Dan Li, Song Shan, et al. · Immunopharmacology and Immunotoxicology · 2
Works count: 37
Citation count: 1,383
H-index: 17
I10-index: 22
Year
Topic
Type